MGNX -- MacroGenics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGNX -- MacroGenics

MGNX 1.590

-6.2%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (154)	2/12/2019 9:25:40 PM
From: Miljenko Zuanic	Read Replies (1) of 188

<Why did they wait 6 days?> My view...to make Leerink's and Evercore's trade more profitable. Or, their CFO is SLOW! (no contacts) PS: I am pissed that my 32.6 order did not went true....other than that, few $ up or down....traders need to make/lose money too. from 424B5 <During the first quarter of 2019, we plan to discuss with the FDA our proposed future development plans for a Phase 2 study of margetuximab in combination with MGA012, an anti-PD-1 monoclonal antibody, which we are planning to initiate in the second half of 2019.>, <Based on these results, we intend to commence Phase 2 studies of enoblituzumab in combination with MGA012 in patients with SCCHN and NSCLC beginning in the second half of 2019.>, bispecific 009 is probably dead, <We have established the dose and schedule for MGD013 administration and initiated dose expansion in up to nine tumor types in a Phase 1 study. We expect to present data from this ongoing study in 2019.<, .... I believe they have sufficient Marg quantity to complete P3 mBC and do P2-gastric. I also believe they will do at least $200M, and from financial stability base seek out Marg partner.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next